Pfizer Inc. failed to convince advisers to the US Food and Drug Administration to support a dramatic expansion in the use of its prostate cancer drug, a setback that could scuttle the company’s ...

In its latest setback, Merck has announced ... in combination with Astellas/Pfizer’s Xtandi (enzalutamide) in metastatic castration-resistant prostate cancer (mCRPC) – its last remaining ...

Pfizer recently presented groundbreaking findings in cancer research, particularly the first-in-human Phase 1 clinical study of the innovative MesoC2 drug at the ASCO Annual Meeting, and announced ...

A U.S. FDA panel of independent experts beat back an effort by Pfizer (NYSE:PFE) to expand the patient population for its prostate cancer treatment Talzenna (talazoparib). Members of the Oncologic ...

The FDA has approved darolutamide without chemotherapy for treatment of metastatic hormone-sensitive prostate cancer.The FDA ...

is the first and only androgen receptor inhibitor to demonstrate an overall survival benefit at five years in men with metastatic hormone-sensitive prostate cancer Data continue to show wide ...

https://www.tipranks.com/news/the-fly/p3-health-partners-price-target-lowered-to-8-from-12-50-at-td-cowen-thefly Astellas Pharma (ALPMY) and Pfizer (PFE) announced ...